Who is sponsoring NCT04667533?

NCT04667533 is sponsored by Zydus Lifesciences Limited.

What drugs are being tested in NCT04667533?

Interventions in NCT04667533: Desidustat.

What condition does NCT04667533 study?

NCT04667533 studies Anemia of Chronic Kidney Disease, Chemotherapy Effect.

Is NCT04667533 still recruiting?

NCT04667533 is currently completed. Last updated 18 May 2022.

Last reviewed 2022-05-18 · How we verify

NCT04667533

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Desidustat in the Treatment of Chemotherapy Induced Anemia

Completed Phase 1 Last updated 18 May 2022

What this trial tests

Phase 1 trial testing Desidustat in Anemia of Chronic Kidney Disease in 24 participants. Completed in 10 May 2022.

Timeline

11 November 2020

Primary endpoint
27 March 2022

10 May 2022

Quick facts

Lead sponsor	Zydus Lifesciences Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	11 November 2020
Primary completion	27 March 2022
Estimated completion	10 May 2022
Sites	1 location across India

Drugs / interventions tested

Desidustat — full drug profile →

Conditions studied

Anemia of Chronic Kidney Disease — all drugs for Anemia of Chronic Kidney Disease →
Chemotherapy Effect — all drugs for Chemotherapy Effect →

Sponsor

Zydus Lifesciences Limited — full company profile →

Who can join

19 and older, any sex, with Anemia of Chronic Kidney Disease or Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, Open-label, Single Dose, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Desidustat for treatment of anemia in patients receiving chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Desidustat: First Approval.
Dhillon S. · · 2022 · cited 19× · PMID 35834123 · DOI 10.1007/s40265-022-01744-w

Verify or expand the search:

Other trials of Desidustat

Trials testing the same drug.

NCT05515367 — A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic · Phase 4 · recruiting
NCT04463602 — Desidustat in the Management of COVID-19 Patients · Phase 2 · completed

Other recruiting trials for Anemia of Chronic Kidney Disease

Currently open trials in the same condition.

NCT06520826 — Vafseo Outcomes In-Center Experience · Phase 3 · active not recruiting
NCT06463236 — Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients · NA · recruiting
NCT05515367 — A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic · Phase 4 · recruiting
NCT05544513 — Oral Iron Supplementation for Patients With Chronic Kidney Disease · Phase 2 · active not recruiting

Other Zydus Lifesciences Limited trials

Trials by the same sponsor.

NCT05911828 — A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combina · Phase 1 · recruiting
NCT06398808 — A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately · Phase 2 · completed
NCT05981040 — Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Scl · Phase 2 · completed
NCT05872269 — A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities · Phase 4 · unknown
NCT05515367 — A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04667533 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zydus Lifesciences Limited
Last refreshed: 18 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04667533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing